Sapu Nano is a clinical-stage biotechnology company developing Deciparticle (TM) nanomedicine therapeutics designed to optimize the delivery of hydrophobic oncology agents and peptide-based ...

Variational AI’s Enki™ generative AI platform designed novel ATR/mTOR dual inhibitors with brain penetrance and activity in ...

Findings from a prospective, randomized trial indicate that wound healing problems observed in early studies of high exposure to mTOR inhibitors can be prevented by using a dual regimen of everolimus ...

Mammalian target of rapamycin (mTOR) inhibitors could be associated with acute nephrotoxicity, according to French researchers. The team describes 4 cancer patients who developed severe acute kidney ...

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of ...

Health related quality of life (HRQOL) evaluated with the EORTC C30 questionnaire in first line therapy of elderly patients with chronic lymphocytic leukemia (CLL): Results of a phase III trial of the ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 38 (September 20, 2022), pp. 1-9 (9 pages) Mammalian target of rapamycin (mTOR) is a highly conserved ...

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform ...

Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables broad and consistent formulation of structurally diverse ...